Reduced-dose venetoclax through intentional CYP inhibition: A reproducible global access strategy with drug price as the residual barrier
- 27 July 2026
- journal article
- letter
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- A prospective observational study to compare the efficacy, time toxicity, and cost of conventional 3+7 regimen versus azacitidine + venetoclax (AZA + VEN) as induction therapy in patients with acute myeloid leukemia (AML).Journal of Clinical Oncology, 2026
- Venetoclax for unfit AML: real-world outcomes of standard and azole-adjusted dosing in Brazilian public and private careBlood Global Hematology, 2026
- Pharmacological boosting of azacitidine/venetoclax in acute myeloid leukemiaBlood Neoplasia, 2026
- Outpatient low-dose venetoclax-azacitidine vs intensive therapy in newly diagnosed AML in resource-limited settingsBlood Global Hematology, 2025
- Combining azole antifungals with venetoclax plus azacitidine in patients with newly diagnosed acute myeloid leukemiaHematology, 2024
- Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemiaBlood Advances, 2021
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaNew England Journal of Medicine, 2020